69 related articles for article (PubMed ID: 1481145)
21. [Analgetic effect of guanfacine in postoperative period].
Strashnov VI; Bogdanov EG
Anesteziol Reanimatol; 1996; (4):43-4. PubMed ID: 8975571
[No Abstract] [Full Text] [Related]
22. [Circadian changes in arterial blood pressure and hemodynamics and the morphofunctional state of the myocardium in patients with hypertension during long-term treatment with estulic].
Komarov FI; Ol'binskaia LI; Iamshchikov SN
Klin Med (Mosk); 1990 Feb; 68(2):58-61. PubMed ID: 2186218
[TBL] [Abstract][Full Text] [Related]
23. A postmarketing evaluation of guanfacine hydrochloride in mild to moderate hypertension.
Board AW; Perry VP; Shepperson BE; Nyman CE; Carchman SH
Clin Ther; 1988; 10(6):761-75. PubMed ID: 3064907
[TBL] [Abstract][Full Text] [Related]
24. [A new antihypertensive agent used in a clinical setting].
Wetzels E; Raschig A; Kaiser HJ
Med Klin; 1980 Sep; 75(19):688-92. PubMed ID: 7001207
[TBL] [Abstract][Full Text] [Related]
25. Prolactin, renin, growth hormone, lipoproteins and glucose under guanfacine treatment.
Hauger-Klevene JH; Balossi EC; Scornavacchi JC
Cor Vasa; 1987; 29(4 Suppl 1):17-22. PubMed ID: 3119290
[TBL] [Abstract][Full Text] [Related]
26. [Antihypertensive therapy with guanfacine. A multicenter trial with Estulic Wander 1 mg].
Schäfer N; Knaup G
MMW Munch Med Wochenschr; 1982 Mar; 124(10):249-52. PubMed ID: 6806612
[No Abstract] [Full Text] [Related]
27. Guanfacine in the treatment of hypertension: two years' experience with low dose monotherapy.
Jerie P; Lasance A
Int J Clin Pharmacol Ther Toxicol; 1981 Jun; 19(6):279-87. PubMed ID: 7030975
[TBL] [Abstract][Full Text] [Related]
28. [Hypotensive effect of oxatriazolium-5-olate derivative].
Artem'eva MM; Postnikov AB; Akinfrieva OV; Daliger IL; Shevelev SA; Medvedev OS; Medvedeva NA
Eksp Klin Farmakol; 2008; 71(5):25-7. PubMed ID: 19093367
[TBL] [Abstract][Full Text] [Related]
29. Guanfacine (Estulic) in the treatment of hypertension.
Cor Vasa; 1987; 29(4 Suppl 1):1-52. PubMed ID: 3315446
[No Abstract] [Full Text] [Related]
30. Comparison of once-daily guanfacine and twice-a-day methyldopa in the treatment of mild to moderate hypertension.
Farooki MS; Farsky K; Bouchard S; Lalonde Y; Brookman S
Clin Ther; 1985; 7(2):199-204. PubMed ID: 3886142
[TBL] [Abstract][Full Text] [Related]
31. Antihypertensive therapy with guanfacine induces elevated plasma growth hormone levels in diabetic patients.
Coves MJ; Gomis R; Casamitjana R; Lienas V; Vilaradell E
J Med; 1989; 20(3-4):291-6. PubMed ID: 2572660
[TBL] [Abstract][Full Text] [Related]
32. Long-term antihypertensive therapy with guanfacine.
Szám I; Holló J
Int J Clin Pharmacol Ther Toxicol; 1982 Aug; 20(8):388-92. PubMed ID: 6749702
[TBL] [Abstract][Full Text] [Related]
33. Hemodynamic effects of guanfacine in essential hypertension.
Feldstein CA; Cohen AA; Sabaris RP; Burucúa JE
Clin Ther; 1984; 6(3):325-34. PubMed ID: 6373009
[TBL] [Abstract][Full Text] [Related]
34. Pharmacokinetics of a guanfacine extended-release formulation in children and adolescents with attention-deficit-hyperactivity disorder.
Boellner SW; Pennick M; Fiske K; Lyne A; Shojaei A
Pharmacotherapy; 2007 Sep; 27(9):1253-62. PubMed ID: 17723079
[TBL] [Abstract][Full Text] [Related]
35. [Blood pressure and renin under treatment of hypertension with guanfacine (author's transl)].
Rosenthal J; Jäger H
MMW Munch Med Wochenschr; 1980 Jan; 122(4):137-40. PubMed ID: 6767938
[TBL] [Abstract][Full Text] [Related]
36. [Improvement of the functional capacity of hypertensive patients treated with guanfacine].
Bazika V; Neuzil P; Tiserová J; Hrabovský F
Cas Lek Cesk; 1986 May; 125(21):637-40. PubMed ID: 3518943
[No Abstract] [Full Text] [Related]
37. Evaluation of the dose-effect relationship of perindopril in the treatment of hypertension.
Luccioni R; Frances Y; Gass R; Gilgenkrantz JM
Clin Exp Hypertens A; 1989; 11 Suppl 2():521-34. PubMed ID: 2605801
[TBL] [Abstract][Full Text] [Related]
38. Phase I, double-blind, randomized, placebo-controlled, dose-escalation study of the effects on blood pressure of abrupt cessation versus taper down of guanfacine extended-release tablets in adults aged 19 to 24 years.
Kisicki JC; Fiske K; Lyne A
Clin Ther; 2007 Sep; 29(9):1967-79. PubMed ID: 18035196
[TBL] [Abstract][Full Text] [Related]
39. [Guanfacine (Estulic) in the monotherapy of essential hypertension, grades I and II, according to WHO].
Mayer K; Lupínek Z; Janousek S; Podrouzková B
Cas Lek Cesk; 1984 Oct; 123(43):1306-11. PubMed ID: 6391673
[No Abstract] [Full Text] [Related]
40. [Minimal useful dose of guanfacine in patients with essential hypertension].
Pérez Olea J; Ortíz N; Soledad Bertoló M; Allel L; Goity C; Quevedo M
Rev Med Chil; 1985 May; 113(5):420-4. PubMed ID: 3912882
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
